Crohn’s disease study identifies genetic variant with potential to personalize treatment

A genetic variant carried by 40% of the population explains why some patients develop antibodies against the anti-TNF drugs, infliximab and adalimumab and lose response. The authors conclude that a further trial is required to confirm that genetic testing prior to treatment will reduce the rate of treatment failure by facilitating the most effective choice of therapy for individual patients. The research is part of a program of work committed to finding the right drug for the right patient first time.